Literature DB >> 18349134

Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury.

Valeria Ramaglia1, Ruud Wolterman, Maryla de Kok, Miriam Ann Vigar, Ineke Wagenaar-Bos, Rosalind Helen Mary King, Brian Paul Morgan, Frank Baas.   

Abstract

Complement activation is a crucial early event in Wallerian degeneration. In this study we show that treatment of rats with soluble complement receptor 1 (sCR1), an inhibitor of all complement pathways, blocked both systemic and local complement activation after crush injury of the sciatic nerve. Deposition of membrane attack complex (MAC) in the nerve was inhibited, the nerve was protected from axonal and myelin breakdown at 3 days after injury, and macrophage infiltration and activation was strongly reduced. We show that both classical and alternative complement pathways are activated after acute nerve trauma. Inhibition of the classical pathway by C1 inhibitor (Cetor) diminished, but did not completely block, MAC deposition in the injured nerve, blocked myelin breakdown, inhibited macrophage infiltration, and prevented macrophage activation at 3 days after injury. However, in contrast to sCR1 treatment, early signs of axonal degradation were visible in the nerve, linking MAC deposition to axonal damage. We conclude that sCR1 protects the nerve from early axon loss after injury and propose complement inhibition as a potential therapy for the treatment of diseases in which axon loss is the main cause of disabilities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349134      PMCID: PMC2276415          DOI: 10.2353/ajpath.2008.070660

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates.

Authors:  B P Morgan
Journal:  Methods Mol Biol       Date:  2000

2.  Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage.

Authors:  P J Chai; R Nassar; A E Oakeley; D M Craig; G Quick; J Jaggers; S P Sanders; R M Ungerleider; P A Anderson
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

Review 3.  Myelin phagocytosis by macrophages and nonmacrophages during Wallerian degeneration.

Authors:  Kazuho Hirata; Masaru Kawabuchi
Journal:  Microsc Res Tech       Date:  2002-06-15       Impact factor: 2.769

4.  Rapid response of identified resident endoneurial macrophages to nerve injury.

Authors:  M Mueller; K Wacker; E B Ringelstein; W F Hickey; Y Imai; R Kiefer
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Lesion response of long-term and recently immigrated resident endoneurial macrophages in peripheral nerve explant cultures from bone marrow chimeric mice.

Authors:  Christine Leonhard; Marcus Müller; William F Hickey; Erich B Ringelstein; Reinhard Kiefer
Journal:  Eur J Neurosci       Date:  2002-11       Impact factor: 3.386

Review 6.  Recent advances in neurotrauma.

Authors:  D I Graham; T K McIntosh; W L Maxwell; J A Nicoll
Journal:  J Neuropathol Exp Neurol       Date:  2000-08       Impact factor: 3.685

7.  Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts.

Authors:  E A Kallio; K B Lemström; P J Häyry; U S Ryan; P K Koskinen
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

8.  Complement-receptor-3 and scavenger-receptor-AI/II mediated myelin phagocytosis in microglia and macrophages.

Authors:  Fanny Reichert; Shlomo Rotshenker
Journal:  Neurobiol Dis       Date:  2003-02       Impact factor: 5.996

Review 9.  Axon pathology in neurological disease: a neglected therapeutic target.

Authors:  Michael P Coleman; V Hugh Perry
Journal:  Trends Neurosci       Date:  2002-10       Impact factor: 13.837

10.  The membrane attack complex of the complement system is essential for rapid Wallerian degeneration.

Authors:  Valeria Ramaglia; Rosalind Helen Mary King; Michelle Nourallah; Ruud Wolterman; Rosalein de Jonge; Marja Ramkema; Miriam Ann Vigar; Sandra van der Wetering; Brian Paul Morgan; Dirk Troost; Frank Baas
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

View more
  13 in total

Review 1.  CR1 in Alzheimer's disease.

Authors:  Xi-Chen Zhu; Jin-Tai Yu; Teng Jiang; Ping Wang; Lei Cao; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

2.  C3-dependent mechanism of microglial priming relevant to multiple sclerosis.

Authors:  Valeria Ramaglia; Timothy R Hughes; Rossen M Donev; Marieta M Ruseva; Xiaobo Wu; Inge Huitinga; Frank Baas; James W Neal; B Paul Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

3.  NF-κB signaling pathway-enhanced complement activation mediates renal injury in trichloroethylene-sensitized mice.

Authors:  Min Liu; Hui Wang; Jiaxiang Zhang; Xiaodong Yang; Bodong Li; Changhao Wu; Qixing Zhu
Journal:  J Immunotoxicol       Date:  2018-12       Impact factor: 3.000

4.  Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Authors:  Isabel Y Pappworth; Christine Hayes; Jason Dimmick; B Paul Morgan; V Michael Holers; Kevin J Marchbank
Journal:  Immunobiology       Date:  2011-06-25       Impact factor: 3.144

Review 5.  Comparative functional evolution of human and mouse CR1 and CR2.

Authors:  Amanda C Jacobson; John H Weis
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

6.  M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator.

Authors:  Nawal Bahia El Idrissi; Pranab K Das; Kees Fluiter; Patricia S Rosa; Jeroen Vreijling; Dirk Troost; B Paul Morgan; Frank Baas; Valeria Ramaglia
Journal:  Acta Neuropathol       Date:  2015-03-15       Impact factor: 17.088

7.  Complement activation at the motor end-plates in amyotrophic lateral sclerosis.

Authors:  Nawal Bahia El Idrissi; Sanne Bosch; Valeria Ramaglia; Eleonora Aronica; Frank Baas; Dirk Troost
Journal:  J Neuroinflammation       Date:  2016-04-07       Impact factor: 8.322

Review 8.  Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis.

Authors:  Marco Mannes; Christoph Q Schmidt; Bo Nilsson; Kristina N Ekdahl; Markus Huber-Lang
Journal:  Semin Immunopathol       Date:  2021-06-30       Impact factor: 9.623

9.  Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves.

Authors:  Jose A Gomez-Sanchez; Lucy Carty; Marta Iruarrizaga-Lejarreta; Marta Palomo-Irigoyen; Marta Varela-Rey; Megan Griffith; Janina Hantke; Nuria Macias-Camara; Mikel Azkargorta; Igor Aurrekoetxea; Virginia Gutiérrez De Juan; Harold B J Jefferies; Patricia Aspichueta; Félix Elortza; Ana M Aransay; María L Martínez-Chantar; Frank Baas; José M Mato; Rhona Mirsky; Ashwin Woodhoo; Kristján R Jessen
Journal:  J Cell Biol       Date:  2015-07-06       Impact factor: 10.539

Review 10.  PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.

Authors:  Barbara W van Paassen; Anneke J van der Kooi; Karin Y van Spaendonck-Zwarts; Camiel Verhamme; Frank Baas; Marianne de Visser
Journal:  Orphanet J Rare Dis       Date:  2014-03-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.